FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129277265> ?p ?o ?g. }

• W2129277265 endingPage "3126" @default.
• W2129277265 startingPage "3119" @default.
• W2129277265 abstract "To test the hypothesis that consolidation therapy with yttrium-90 ((90)Y) -ibritumomab tiuxetan after brief initial therapy with four cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated mantle-cell lymphoma would be a well-tolerated regimen that would improve outcomes compared with historical R-CHOP data.Patients ≥ 18 years old with histologically confirmed mantle-cell lymphoma expressing CD20 and cyclin D1 who had not received any previous therapy and had an Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were eligible. The study enrolled and treated 57 patients, of whom 56 patients were eligible. Fifty-two patients (50 eligible patients) received (90)Y-ibritumomab tiuxetan. The study design required 52 eligible patients to detect a 50% improvement in the median time to treatment failure (TTF) compared with that reported for six cycles of R-CHOP.With 56 analyzed patients (median age, 60 years; men, 73%), the overall response rate was 82% (55% complete response/complete response-unconfirmed). With a median follow-up of 72 months, the median TTF was 34.2 months. The median overall survival (OS) has not been reached, with an estimated 5-year OS of 73% (79% for patients ≤ age 65 years v 62% for patients > age 65 years; P = .08 [log-rank test]). There were no unexpected toxicities.R-CHOP given for four cycles followed by (90)Y-ibritumomab tiuxetan compared favorably with historical results with six cycles of R-CHOP in patients with previously untreated mantle-cell lymphoma. This regimen was well tolerated and should be applicable to most patients with this disease." @default.
• W2129277265 created "2016-06-24" @default.
• W2129277265 creator A5012750761 @default.
• W2129277265 creator A5029655862 @default.
• W2129277265 creator A5031758990 @default.
• W2129277265 creator A5039809944 @default.
• W2129277265 creator A5060314041 @default.
• W2129277265 creator A5069033960 @default.
• W2129277265 creator A5069054551 @default.
• W2129277265 creator A5075568815 @default.
• W2129277265 creator A5079511754 @default.
• W2129277265 creator A5089854184 @default.
• W2129277265 date "2012-09-01" @default.
• W2129277265 modified "2023-10-15" @default.
• W2129277265 title "Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499" @default.
• W2129277265 cites W1549556227 @default.
• W2129277265 cites W1985343909 @default.
• W2129277265 cites W1996537666 @default.
• W2129277265 cites W2001178238 @default.
• W2129277265 cites W2020764618 @default.
• W2129277265 cites W2029511375 @default.
• W2129277265 cites W2039021803 @default.
• W2129277265 cites W2069096955 @default.
• W2129277265 cites W2082584333 @default.
• W2129277265 cites W2101648653 @default.
• W2129277265 cites W2105351857 @default.
• W2129277265 cites W2107202569 @default.
• W2129277265 cites W2115577067 @default.
• W2129277265 cites W2124235514 @default.
• W2129277265 cites W2125684345 @default.
• W2129277265 cites W2127249281 @default.
• W2129277265 cites W2128957975 @default.
• W2129277265 cites W2130093747 @default.
• W2129277265 cites W2130669641 @default.
• W2129277265 cites W2132443196 @default.
• W2129277265 cites W2132678616 @default.
• W2129277265 cites W2150280279 @default.
• W2129277265 cites W2151092645 @default.
• W2129277265 cites W2155713523 @default.
• W2129277265 cites W2155724413 @default.
• W2129277265 cites W2162109567 @default.
• W2129277265 cites W3012015733 @default.
• W2129277265 cites W4205736005 @default.
• W2129277265 doi "https://doi.org/10.1200/jco.2012.42.2444" @default.
• W2129277265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3732008" @default.
• W2129277265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22851557" @default.
• W2129277265 hasPublicationYear "2012" @default.
• W2129277265 type Work @default.
• W2129277265 sameAs 2129277265 @default.
• W2129277265 citedByCount "78" @default.
• W2129277265 countsByYear W21292772652013 @default.
• W2129277265 countsByYear W21292772652014 @default.
• W2129277265 countsByYear W21292772652015 @default.
• W2129277265 countsByYear W21292772652016 @default.
• W2129277265 countsByYear W21292772652017 @default.
• W2129277265 countsByYear W21292772652018 @default.
• W2129277265 countsByYear W21292772652019 @default.
• W2129277265 countsByYear W21292772652020 @default.
• W2129277265 countsByYear W21292772652021 @default.
• W2129277265 countsByYear W21292772652022 @default.
• W2129277265 crossrefType "journal-article" @default.
• W2129277265 hasAuthorship W2129277265A5012750761 @default.
• W2129277265 hasAuthorship W2129277265A5029655862 @default.
• W2129277265 hasAuthorship W2129277265A5031758990 @default.
• W2129277265 hasAuthorship W2129277265A5039809944 @default.
• W2129277265 hasAuthorship W2129277265A5060314041 @default.
• W2129277265 hasAuthorship W2129277265A5069033960 @default.
• W2129277265 hasAuthorship W2129277265A5069054551 @default.
• W2129277265 hasAuthorship W2129277265A5075568815 @default.
• W2129277265 hasAuthorship W2129277265A5079511754 @default.
• W2129277265 hasAuthorship W2129277265A5089854184 @default.
• W2129277265 hasBestOaLocation W21292772652 @default.
• W2129277265 hasConcept C126322002 @default.
• W2129277265 hasConcept C141071460 @default.
• W2129277265 hasConcept C159654299 @default.
• W2129277265 hasConcept C203014093 @default.
• W2129277265 hasConcept C2776146153 @default.
• W2129277265 hasConcept C2776694085 @default.
• W2129277265 hasConcept C2776755627 @default.
• W2129277265 hasConcept C2777525834 @default.
• W2129277265 hasConcept C2778476033 @default.
• W2129277265 hasConcept C2778515704 @default.
• W2129277265 hasConcept C2778720950 @default.
• W2129277265 hasConcept C2779338263 @default.
• W2129277265 hasConcept C2779429289 @default.
• W2129277265 hasConcept C2779725641 @default.
• W2129277265 hasConcept C2780653079 @default.
• W2129277265 hasConcept C2781413609 @default.
• W2129277265 hasConcept C542903549 @default.
• W2129277265 hasConcept C71924100 @default.
• W2129277265 hasConcept C90924648 @default.
• W2129277265 hasConceptScore W2129277265C126322002 @default.
• W2129277265 hasConceptScore W2129277265C141071460 @default.
• W2129277265 hasConceptScore W2129277265C159654299 @default.
• W2129277265 hasConceptScore W2129277265C203014093 @default.
• W2129277265 hasConceptScore W2129277265C2776146153 @default.
• W2129277265 hasConceptScore W2129277265C2776694085 @default.
• W2129277265 hasConceptScore W2129277265C2776755627 @default.

• next